株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

鼻咽頭炎(感冒):パイプライン分析

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 229834
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.80円で換算しております。
Back to Top
鼻咽頭炎(感冒):パイプライン分析 Nasopharyngitis (Common Cold) - Pipeline Review, H2 2017
出版日: 2017年07月11日 ページ情報: 英文 33 Pages
概要

鼻咽頭炎には、発熱に伴う鼻炎・咽頭炎が発症するという特徴があります。また、幼児に非常によく見られる疾患です。ウイルスにより発症するため、治療や化学的予防の段階では、たいていは抗菌剤は必要ではありません。解熱剤(児童向けには非アスピリン性のもの)で高熱をおさえることができます。

当レポートでは、世界各国での鼻咽頭炎(感冒)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

鼻咽頭炎の概要

治療薬の開発

  • 鼻咽頭炎向けパイプライン製品:概要
  • 鼻咽頭炎向けパイプライン製品:比較分析

各企業で開発中の鼻咽頭炎治療薬

大学/研究機関で研究中の鼻咽頭炎治療薬

パイプライン製品の概略

  • 初期段階の製品
  • 不明確な段階にある製品

鼻咽頭炎治療薬:開発中の製品の一覧(企業別)

鼻咽頭炎治療薬:研究中の製品の一覧(大学/研究機関別)

鼻咽頭炎治療薬の開発に従事している企業

  • Charleston Laboratories, Inc.
  • Cocrystal Pharma, Inc.
  • Neos Therapeutics, Inc.
  • Orbis Biosciences, Inc.
  • Vernalis Plc

鼻咽頭炎:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (マレイン酸クロルフェニラミン + コデイン)
  • TRIM-21を標的とする消化器疾患/耳鼻咽頭疾患向け抗体
  • CCP-05
  • CCP-06
  • CCP-07
  • CCP-08
  • CLAT-313
  • グアイフェネシン ER
  • 咳/風邪向け小分子
  • 喘息/風邪向けのMAPK13抑制分子
  • 一般的な風邪向けのRNA依存性RNAポリメラーゼ抑制分子
  • ■鼻咽頭炎治療薬:最新の薬剤プロファイル

鼻咽頭炎治療薬:開発が休止状態の製品

鼻咽頭炎治療薬:開発が中止された製品

鼻咽頭炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9519IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngitis (Common Cold) - Pipeline Review, H2 2017, provides an overview of the Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline landscape.

Nasopharyngitis also known as common cold is an infectious, inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngitis (Common Cold) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn and Preclinical stages are 1, 1 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nasopharyngitis (Common Cold) - Overview
    • Nasopharyngitis (Common Cold) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Nasopharyngitis (Common Cold) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development
    • Charleston Laboratories Inc
    • Orbis Biosciences Inc
    • Vernalis Plc
  • Nasopharyngitis (Common Cold) - Drug Profiles
    • Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-07 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • guaifenesin ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydrocodone bitartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORB-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit MAPK13 for Asthma and Cold - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nasopharyngitis (Common Cold) - Dormant Projects
  • Nasopharyngitis (Common Cold) - Discontinued Products
  • Nasopharyngitis (Common Cold) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
      • Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
      • Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
      • Oct 10, 2013: Spriaso completes FDA Meeting on Tuxarin ER
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Nasopharyngitis (Common Cold), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories Inc, H2 2017
  • Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences Inc, H2 2017
  • Nasopharyngitis (Common Cold) - Pipeline by Vernalis Plc, H2 2017
  • Nasopharyngitis (Common Cold) - Dormant Projects, H2 2017
  • Nasopharyngitis (Common Cold) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Nasopharyngitis (Common Cold), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top